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IN a previous communication (Barker, Dhar and Parsons, 1949) the effects on
sarcoma growth in mice produced by treatment with some derivatives ofpurine
andpyrimidine compounds were recorded. Furtherexperiments described below
have extended the range ofpyrimidine compounds studied, and an attempt has
been made to correlate molecular structure with biological activity. The com-
pounds employed fall into the foRowing groups:
(1) Cytidyfic acid and alhed compounds.
(2) Barbituric acid, its imino derivatives and related compounds.
(3) Acyclic analogues of some ofthe above compounds.
Pure line or stock mice were grafted with the homologous C57 or the hetero-
logous 837 or Crocker sarcomas. The technique for treatment was similar to
that previously described (Barakan, Barker, GuBand and Parsons, 1948), the
standard dose (0-025 g.) being reclueed in proportion to the toxicity of the par-
ticular compound. Heavy mortality occurred amongst mice treated with 2:4:6-
triaminopyrimidine,4:6-diaminopyrim dine andaBoxan. Table I summarizes the
results obtained. Statistical analysis has shown that the differences in tumour
weights for treated and untreated grafted mice are significant for Groups 2, 10,
II and 12. In all groups the number of controls equalled the number of treated
mice.
(1) Cytidylic acid and allied compounds.
The effects on sa'reoma growth in grafted mice treated with the four nucleo-
tides of ribonucleic acid have been described in earlier reports (Parsons, Gulland
and Barker, 1947; Barakan, Barker, GuHand and Parsons, 1948; Barker, Dhar
and Parsons, 1949). In the course of these experiments it had been noted that
the ratios of tumour weights in treated and control mice were not appreciably
altered by substitution of the corresponding nucleoside or the free pyrimidine
orpurine foruridyhc,adenyhc orguanyhc acids, the small differences in behaviour
within each group being almost certainly due to differences insolubility in water.
No such comparison was made, however, in the'eytidyhc acid series, since this
nucleotide had been found to have little if any action on sarcoma development.
Recent obseirvations (Brown, 1950 ; Hammarsten, Reichard and Saluste,
1950 ; Bendich, Getler and Brown, 1949) have shown that in rats fed with the
pyrimidine nucleosides, cytidine or uridine, whereas cytidine is an effective pre-ACTION OF PYRIMIDINE DERIVATIVES 125
TABLEI.-Total Tumour Weight8ofTreated and Untreated Mice.
Number of Total wt.
mice oftreated
treated. tumours.
g. (T).
12 39-0
25 52- 9
40- 8
38 73-4
28 71-4
27 54- 5
15 30- 9
10 19- 7
16 27- 1
30 67
- 7
25 28- 6
21 61- 6
56 51-4
24 48- 3
27 48- 6
35 46-0
19 33- 7
Total wt.
of control
tumours.
g. (c):
1 38- 1
1 40- 1
41-0
76- 2
72- 7
63- 8
35- 6
22-4
28- 6
1 70- 3
56- 0
37
- 0
88- 0
58- 2
46- 3
51- 9
28-4
Ratio
T/C
1.00
1- 32
0.99
0- 96
0- 98
0- 86
0- 87
0- 87
0.95
0- 96
0.51
1- 66
0- 58
0- 82
1- 04
. .0- 88
1- 18
Compound.
Cystosine
Isocytosine
Arginine
Alloxan
Uramil .'
5-Aminouracil (Group
5-Aminouracil (Group
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
IL
12.
13.
M.
1).
2).
2-Thio-4-amino-6-oxypyrimidine
Barbituric acid : 2-Amino-4:6-dioxypyrimidine
.
4:6-Diarnino-2-oxypyrimidine
.
2:4-Diamino-6-oxypyrimidine
.
2:4:6-Triaminopyrimidine
4:6-Diaminopyrimidine
Acetamidine hydrochloride
15. Acetyl urea .
16. Carbamido-acetamidine .
cursor ofboth thecytosine and uracil ofnucleic acid, uridine is arelativelyineffec-
tive p-recursor ofeither. Cytosine and uracil, on the other hand, are not utilized
in nucleic acid synthesis. This suggested that examination should be made of
the action of cytosine when injected into grafted mice. A small number of
sarcoma-bearing mice were therefore treated with this compound, which was
found to have a negfigible effect on tumour development. Isocytosine (2-amino-
6-oxypyrimidine), on the otherhand, in which thepositions ofthe amino and oxy
groups in cytosine are reversed, had a moderate acceleratory action. This
findin is ofinterest, since the closely related compound 2:4-dianuino-6-oxypyri-
midine induces a similar, though more considerable, effect in grafted tumours,
and this action becomesinhibitoryagain onreversing the amino and oxy groups in
positions 2 and 6 ofthe molecule.
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It would seem from the above results that the cytosine molecule can exert
no action when injected subcutaneously into grafted mice, whether it is adminis-
tered as the free pyrimidine or combined with a ribose residue as in cytidylic126 G. R. BARKER, M. M. DHAR AND L. D. PARSONS
acid: the differences in metabolic behaviour between such compounds adminis-
teredoraHyevidentlyhave nobearing ontheiractions ontumours wheninjected.
There is evidence (Cerecedo, 1927) that cytosine adniinistered orally to dogs
is partly excreted unchanged and partly deaminated to uracil. Cytidine, on the
other hand, is excreted as urea (Emerson and Cerecedo, 1930). Furthermore,
after oral administration to rats, 87-3 per cent ofcytosine nitrogen is excreted in
six days (Bendich, Getler and Brown, 1949). In contrast to these examples of
oral administration, subcutaneous or intraperitoneal injection of cytosine into
various animals (Mendel andMyers, 1910) results intheexcretion ofthecompound
unchanged and no ura'cil was observed in the urine. In the present series of
experiments no evidence has been obtained on the fate of the injected materials,
but it is reasonable to assume that, in agreement with Mendel and Myers (1910),
simple deamination of cytosine or cytidylic acid does not take place, since the
products would have an acceleratory effect on tumour growth.
The fate of in ected nucleotides is being examined by different methods and
will be reportedseparately, but the problem has also beenapproached by astudy of the effects on tumour growth ofpossible precursors and degradation products of purine and pyrim dine compounds. In a previous communication (Barker,
Dhar and Parsons, 1949) 4-carboxyuracil (orotic acid), which has been reported
(Hammarsten, Reichard and Saluste, 1949) as a precursor ofuridine andcytidine,
was found to be inactive when tested in grafted mice. Similarly argmine, which
has been discussed (Hopkins, 1916) as a source ofpurine nitrogen, shows neither
acceleratory nor inhibitory properties. Alloxan and uramil, which might also
arise by oxidative degradation of purines and pyrimidines, have no effect on
tumourdevelopment wheninjected. Injectionof alloxan induced a characteristic
red colour in the urine of the treated mice, suggesting that a proportion at least
of the compound was excreted unchanged.
(2) Barbituric acid, it8 derivatiM andrelated compound8.
As a possible interpretation of the earlier observation (Barker, Dhar and
Parsons, 1949) that 4-aminouracil exhibits a significant inhibition of tumour
growth, it had been suggested that this compound might act as a precursor of
inhibitory bases, and in agreement with this view 4-methyluracil and 5-methyl-4-
aminouracfl, in which conversion to purine is blocked, were found not to have
inhibitory properties. If the amino group is su-bstituted in position 5 the result-
ing compound is also found to be without inhibitory activity. The behaviour
of 4-aminouracil appears to be specifically associated with its chemical structure,
since theintroduction of the sulphur atom at position 2 to give 2-thio-4-amino-6-
oxypyrimidine is sufficient to abohsh its inhibitory action. It is considered
possible that the marked difference in activity between 4-aminouracil and 5-
aminouracil is due to the difference in theelectron-availability at thefreepositions of the two molecules (positions 4 and 5 respectively), which would influence the
abihty ofthe tissues to metabohze the compounds by oxidation.
Since 4-aminouracil may also be regarded in its tautomeric form as 4-imino-
barbituricacid, asystematicstudy was made ofbarbituric acid and itsderivatives,
all of which are characterized by high chemical reactivity at position 5. From
the'results shown in Table I it is clear that the barbituric acid structure cannot
beresponsible for theinhibitory action of4-am'm-ouracil. Barbituric acidinjected127 ACTION OF PYRIMIDINE DERIVATIVES
in tumour-bearing mice was found to be inactive, as was also 2-amino-4:6-dioxy-
pyrimidine, which is isomeric with 4-aminouracil.
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Furthermore, the two isomeric di-imino-derivatives of barbituric acid differ
markedly in their behaviour (see above), 4:6-diamino-2-oxy-pyrirnidine having
similaractivity to 4-aminouracil, whereas2:4-diamino-G-oxypyrimidine has a very
considerable acceleratory effect. Bearing in mind the respective behaviour of
the two mono-imino and the two di-imino derivatives of barbituric acid, it would
seem that the 4-amino group, and to a lesser degree the 6-amino group, make a
contribution to the biological action of these compounds diametricany opposed
to that made by the imino group in position 2. It is not surprising, therefore,
that 2:4:6-triaminopyrimidine has been found to have inhibitory properties, since
in this molecule the effect of the 2-amino group is counterbalanced by the two
4copposing
" amino groups at positions 4 and 6.
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The inhibition of tumour growth observed with 4-aminouracil and with 4:6-
diamino-2-oxypyrimidine does not appear, however, to be entirely due to the
activity of the amino groups, since 4:6-diamino-pyrimidine exerts little ff any inhibitory action, indicating that the 2-oxy group makes a positive contribution
to the actions oftheinhibitorycompounds. Thepossibility has beenput forward
that 4-aminouracil can act as a purine precursor, and the presence of amino
groups in positions 4 and 6 in the di-amino pyrimidine compound suggests from its similar structure that this compound may also play a part in adenine
synthesis.
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(3) The 8pecificity of the heterocyclic ring.
In the above discussio'n of the biological act'ivity of the varl'OUS constituent
groups in the pyrimidine derivati-ves the structures were considered only as part
of the heterocychc system. In order to determi e whether the ring structure of
the compounds is essential to the activities observed three acychc compounds
have been tested. In thefirst, carbamido-acetamidine, the whole ofthe structure
of 4-aniinouracil is present except for the carbon atom at position 2. In the
second, acetyl urea, the configurations at positions 1, 2, 3 and 6 of 4-aminouracil
are inaitated. The third, acetamidine, possesses a similar grouping of atoms to
that at position 4 of 4-aminouracil. None of these compounds, when tested
i
sarcoma-bearing mice, were found to exert inhibitory activity, like 4-aminouracil
or 4:6-diamino-2-oxypyrimidine.
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4-Aminouracil. Carbamido-acetamidine. Acetyl urea. Acetamidine.
The productionof 8hOck.
In the use of compounds examined for their effects on tumour growth, diffi-
culty in assessment ofthe value of the results is occasioned both by the toxicity
of some ofthe compounds and also by the inducement ofshockduring treatment.
It hasalready been statedthat doses varyaccording tothe condition ofthetreated
mouse, and this must preclude any quantitative comparisons. There is also the
possibility that apparent inhibitions of tumour development may be only a
reflection of the general effects of a drug on the body tissues. It is signific-ant,
however, that when alloxan or barbituric acid is administered, although marked
wasting and loss of total body weight occur, the tumours continue to grow with
the same rapidity as those in the control mice.
It has been previously suggested (Barker, Dhar and Parsons, 1949) that the
propert-v of inducing shock shown b adenyhc acid, adenosine and adenine is
associated with the amino group at position 6. This generahzation appeared to
be confirmed when it was found that 4:6-diaminopyrimidine and 2:4:6-triamino-
pyrimidine, which possess part of the adenine structure, also produce shock on
injection, though of a milder type than that caused by injection of adenine. It
is noteworthy that no shock is induced on injectio'n of 4-aminouracil or 4:6-dia-
amino-2-oxypyrimidine, which suggests that the presence of the 2-oxy group
prevents the occurrenceofshock. Whenitisconsidered, moreover, thathypoxan-
thine induces no shock as compared with that caused by adenine, it appearsthat
substitution of an ox group at position 6 is also effective in preventing
shock. It seems, therefore, that the state of oxidation and/or amination of the
pyrimidine ring may play an essential part in the prevention ofshock.ACTION OF PYRIMIDINE DERIVATIVES 129
SUMMARY.
(1) The effects on tumour development of a series of pyrimidine compounds
injected intografted mice have been examined. Ofthe compounds tested 4:6-di-
amino-2-oxypyrimidine and 2:4:6-triaminopyrimidine exhibit inhibitory activity.
Reversal of the amino and oxy groups at positions 6 and 2 in the first-named
compound reverses also the action of the drug and converts an inhibitorv eff6ct
into an acceleratory. S14milarly it has been found that reversal of the saite
groups in the cytosine molecule converts the negative, action of this compound
into a moderate acceleratory effect.
(2) The action on sarcoma growth.of certain acychc compounds injected in
grafted mice and compared with those induced by 4-aminouracil have been found
to be negative.
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